CO2022010294A2 - Anticuerpos cd163 o proteinas de union - Google Patents
Anticuerpos cd163 o proteinas de unionInfo
- Publication number
- CO2022010294A2 CO2022010294A2 CONC2022/0010294A CO2022010294A CO2022010294A2 CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2 CO 2022010294 A CO2022010294 A CO 2022010294A CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2
- Authority
- CO
- Colombia
- Prior art keywords
- porcine
- antigen
- binds
- amino acid
- binding domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona un anticuerpo monoclonal que se une a CD163 porcino para su uso en el tratamiento o prevención de la infección por el virus del síndrome reproductivo y respiratorio porcino (PRRS) en un cerdo. Los anticuerpos preferidos comprenden un dominio de unión a antígeno que se une a CD163 porcino, comprendiendo dicho dominio de unión a antígeno al menos una región variable de la cadena pesada que comprende tres regiones determinantes de la complementariedad (CDR), en donde dicha región variable de la cadena pesada comprende una CDR2 pesada variable (VH) que comprende la secuencia de aminoácidos XYAD o XYAE o XYAN, en la que X puede ser cualquier aminoácido. También se proporcionan moléculas de ácido nucleico, vectores de expresión y composiciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1919294.7A GB201919294D0 (en) | 2019-12-24 | 2019-12-24 | Antibodies or binding proteins |
| PCT/GB2020/053370 WO2021130502A1 (en) | 2019-12-24 | 2020-12-24 | Cd163 antibodies or binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022010294A2 true CO2022010294A2 (es) | 2022-10-31 |
Family
ID=69322779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0010294A CO2022010294A2 (es) | 2019-12-24 | 2022-07-21 | Anticuerpos cd163 o proteinas de union |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230203185A1 (es) |
| EP (1) | EP4081542A1 (es) |
| JP (1) | JP2023508674A (es) |
| KR (1) | KR20220119147A (es) |
| CN (1) | CN115151569A (es) |
| BR (1) | BR112022012362A2 (es) |
| CA (1) | CA3162664A1 (es) |
| CL (1) | CL2022001706A1 (es) |
| CO (1) | CO2022010294A2 (es) |
| DO (1) | DOP2022000136A (es) |
| GB (1) | GB201919294D0 (es) |
| MX (1) | MX2022007957A (es) |
| PE (1) | PE20230384A1 (es) |
| WO (1) | WO2021130502A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7459354B2 (ja) * | 2022-07-08 | 2024-04-01 | ノヴォ ノルディスク アー／エス | ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物 |
| GB202214979D0 (en) * | 2022-10-11 | 2022-11-23 | Eco Animal Health Ltd | Binding protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4361279A2 (en) * | 2015-08-06 | 2024-05-01 | The Curators of the University of Missouri | Pathogen-resistant animals having modified cd163 genes |
| US11160260B2 (en) * | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
-
2019
- 2019-12-24 GB GBGB1919294.7A patent/GB201919294D0/en not_active Ceased
-
2020
- 2020-12-24 BR BR112022012362A patent/BR112022012362A2/pt unknown
- 2020-12-24 MX MX2022007957A patent/MX2022007957A/es unknown
- 2020-12-24 WO PCT/GB2020/053370 patent/WO2021130502A1/en active Search and Examination
- 2020-12-24 PE PE2022001329A patent/PE20230384A1/es unknown
- 2020-12-24 EP EP20838276.2A patent/EP4081542A1/en active Pending
- 2020-12-24 KR KR1020227025626A patent/KR20220119147A/ko unknown
- 2020-12-24 CA CA3162664A patent/CA3162664A1/en active Pending
- 2020-12-24 US US17/788,539 patent/US20230203185A1/en active Pending
- 2020-12-24 JP JP2022539134A patent/JP2023508674A/ja active Pending
- 2020-12-24 CN CN202080097372.4A patent/CN115151569A/zh active Pending
-
2022
- 2022-06-20 CL CL2022001706A patent/CL2022001706A1/es unknown
- 2022-06-23 DO DO2022000136A patent/DOP2022000136A/es unknown
- 2022-07-21 CO CONC2022/0010294A patent/CO2022010294A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001706A1 (es) | 2023-05-26 |
| US20230203185A1 (en) | 2023-06-29 |
| MX2022007957A (es) | 2022-10-07 |
| CA3162664A1 (en) | 2021-07-01 |
| CN115151569A (zh) | 2022-10-04 |
| DOP2022000136A (es) | 2022-11-30 |
| KR20220119147A (ko) | 2022-08-26 |
| BR112022012362A2 (pt) | 2022-09-06 |
| WO2021130502A1 (en) | 2021-07-01 |
| PE20230384A1 (es) | 2023-03-06 |
| JP2023508674A (ja) | 2023-03-03 |
| EP4081542A1 (en) | 2022-11-02 |
| GB201919294D0 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010294A2 (es) | Anticuerpos cd163 o proteinas de union | |
| BR112017027877A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico isolado, vetor, célula hospedeira, método para preparar o anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, cepa de célula hibridoma lt005, conjugado, conjugado de anticorpo bifuncional, anticorpo multiespecífico, composição farmacêutica e uso do anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo | |
| IL299221A (en) | CD3 binding antibodies | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR112257A1 (es) | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| CL2021000739A1 (es) | Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| RS53258B (en) | HUMAN ANTIBODIES AGAINST HEPATITIS C (HCV) VIRUS AND USE | |
| PE20141433A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos | |
| AR065312A1 (es) | Nuevos anticuerpos | |
| EA201792329A1 (ru) | Способ мономеризации рекомбинантных молекул антител | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| DOP2023000130A (es) | ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31 | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc | |
| AR126971A1 (es) | Composiciones y métodos para tratar el síndrome de qt largo | |
| EA201991510A1 (ru) | Каркасы антител для снижения агрегирования полиспецифических антител | |
| WO2022026807A3 (en) | Antibodies targeting sars-cov-2 and uses thereof | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. |